Probenecid Administration for Alcohol Craving and Consumption
Key facts
- Who runs it
- Brown University
- Where
- Providence, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 14 Mar 2026
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Probenecid Oral Tablet
- Placebo Oral Tablet
- Record updated
- 17 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- • Male or female, ≥18 years; women >7 drinks/week; men >14 drinks/week; meet moderate to severe AUD score for DSM-5 criteria; Breath Alcohol Content (BrAC)=0.00 at each visit; in good health as confirmed by medical history, physical examination and lab tests; willing to adhere to the study procedures; understand informed consent and questionnaires in English at an 8th grade level
Who cannot take part
- • Women who are breastfeeding or positive urine test for pregnancy; clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin >150% of the upper normal limit, ALT/AST >300% the UNL, creatinine clearance ≤60 dl/min; meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses; medications that reduce alcohol consumption (naltrexone, disulfiram); use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration); history of suicide attempts in the last three years; current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline; current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline; current use of medications that may interact with probenecid; history of hypersensitivity to sulfa drugs
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Alcohol use disorder or alcohol consumption or craving
This trial is currently available in United States.
- Brown UniversityProvidence, United StatesContact: Brian Gully, MATaking people
About the trial
What the trial wants to find out
This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.
The 2 groups in the trial
- Study drugTreatment being tested
Probenecid 2gr oral
Treatment: Probenecid Oral Tablet
- PlaceboPlacebo, for comparison
Placebo inactive
Treatment: Placebo Oral Tablet
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Probenecid, Pannexin 1 Channels for Alcohol Use Disorder
- Criteria questions
- Built from NCT07118618, who can take part
- Record updated
- 17 March 2026